Anzeige
Mehr »
Login
Mittwoch, 16.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Antimon bei 59.000 USD/ t - Global Tactical's Antimonminen in den USA mit 32,95 % Gehalt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2LQV6 | ISIN: US48251W1045 | Ticker-Symbol: KR51
Tradegate
16.04.25
09:40 Uhr
90,26 Euro
-2,09
-2,26 %
1-Jahres-Chart
KKR & CO INC Chart 1 Jahr
5-Tage-Chart
KKR & CO INC 5-Tage-Chart
RealtimeGeldBriefZeit
89,9791,1009:40
89,9791,1009:40
PR Newswire
316 Leser
Artikel bewerten:
(2)

EQT to sell Karo Healthcare, a Leading Pan-European Consumer health Platform, to KKR

Finanznachrichten News
  • Under EQT's ownership, Karo has transformed from a Nordic specialty pharma business into a pan-European consumer healthcare platform, driven by strong organic growth, eight strategic acquisitions, and investment in digitalisation and in-house commercial capabilities
  • KKR will support Karo's continued growth by leveraging its deep sector expertise, global network, and a long-term investment approach to drive innovation, internationalization, and further brand growth and acquisitions
  • Karo now operates a diversified portfolio of trusted consumer health brands with leadership positions in European markets and a scalable, digitally enabled platform

STOCKHOLM, April 9, 2025 /PRNewswire/ -- EQT and KKR today announced that EQT VIII fund ("EQT") has agreed to sell Karo Healthcare ("Karo" or the "Company") to KKR. The acquisition marks the next chapter for Karo, as it continues to accelerate its growth strategy under KKR's ownership, building on its transformation into one of Europe's leading consumer health platforms since EQT's initial investment.

Karo is a leading pan-European consumer healthcare company headquartered in Stockholm, Sweden. The Company operates an attractive product portfolio spanning core categories such as Skin Health, Foot Health, and Intimate Health, as well as Digestive Health and Vitamins, Minerals & Supplements. During the past five years, Karo has scaled substantially, quadrupling in sales, building leading digital capabilities and establishing market presence to reach consumers in more than 90 countries with top brand positions across European markets.

Under EQT's ownership since 2019, Karo has undergone a significant strategic repositioning, shifting from a specialty pharmaceutical company focused on the Nordics into becoming a pan-European pure-play consumer healthcare platform. During this time, with M&A having been a cornerstone of Karo's growth strategy, Karo completed eight acquisitions from industry players which have enriched Karo's portfolio, strengthened its presence in key markets, and accelerated its entry into new geographies.

Commenting on the transaction, Christoffer Lorenzen, CEO of Karo Healthcare, said: "We're incredibly proud of what we've achieved in recent years and grateful to EQT for their partnership, which has been instrumental in helping us grow and evolve into the business we are today. With KKR as our new owner, we are entering an exciting next phase in our journey. Their global reach, deep sector understanding, and long-term approach make them the ideal strategic partner as we continue to invest in our brands, expand into new markets and meet the evolving health needs of consumers."

"Karo is a textbook example of EQT's approach - scaling a local company into a fast-growing sector champion with international reach," said Erika Henriksson, Partner in the EQT Private Equity advisory team. "Thanks to its consumer centricity, strong M&A track record, and proven brand growth playbooks, Karo is now primed to further expand on its leadership position. We're proud of what Christoffer and the team have achieved and excited to hand over to a new owner for the next phase."

Inaki Cobo, Partner at KKR, said: "Karo is a unique platform with high-quality brands, strong digital and commercial capabilities, and a proven strong leadership team. We are thrilled to invest in this European champion's next phase of growth, drawing on our deep experience in the consumer health space to support continued expansion, innovation, and organic and inorganic growth." Hans Arstad, Managing Director at KKR, added: "Karo operates in a resilient, growing sector supported by long-term demographic trends and increasing consumer focus on wellness and self-care. We engaged the full capabilities of our firm to deliver this transaction during a period of market disruption and we look forward to supporting Karo's growth as a value-enhancing strategic partner."

The transaction is subject to customary regulatory conditions and approvals and is expected to close in the coming months. EQT was advised by Morgan Stanley, Jeffries, White & Case and PwC. Citigroup acted as financial advisor to KKR.

Media Contacts
EQT Press Office, press@eqtpartners.com
KKR, Alastair Elwen, alastair.elwen@fgsglobal.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/eqt-to-sell-karo-healthcare--a-leading-pan-european-consumer-health-platform--to-kkr,c4133227

The following files are available for download:

https://mb.cision.com/Main/87/4133227/3378305.pdf

PR_EQT to sell Karo to KKR_09.04.25

https://news.cision.com/eqt/i/karo-healthcare,c3397143

Karo Healthcare

Cision View original content:https://www.prnewswire.co.uk/news-releases/eqt-to-sell-karo-healthcare-a-leading-pan-european-consumer-health-platform-to-kkr-302424403.html

© 2025 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.